<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144285</url>
  </required_header>
  <id_info>
    <org_study_id>15200</org_study_id>
    <secondary_id>I7C-MC-FEAA</secondary_id>
    <nct_id>NCT02144285</nct_id>
  </id_info>
  <brief_title>A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis</brief_title>
  <official_title>A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Healthy Subjects and Patients With Chronic Kidney Disease Treated With Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the tolerability and safety of LY3113593. Study
      doctors will see how safe it is and whether it produces side effects following a single
      injection into a vein or under the skin in healthy participants (Part A) and participants
      with chronic kidney disease treated with hemodialysis (Part B). The study will also measure
      how much of the study drug gets into the blood stream, how long it takes the body to get rid
      of the study drug and what effects the study drug has on the body.

      This is the first time that this study drug is being given to participants. This study is for
      research purposes only and is not intended to treat any medical condition. For each
      participant, the study will last about 85 days, not including screening. Screening is
      required within 28 days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through end of study (Day 85)</time_frame>
    <description>The number of participants with 1 or more SAEs assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3113593</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 2 hours, 4 hours, 12 hours; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve to Infinity (AUC (0-∞)) of LY3113593</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 2 hours, 4 hours, 12 hours; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Absolute Bioavailability of LY3113593 SC Versus IV Based on AUC Ratios</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 2 hours, 4 hours, 12 hours; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Maximum Change From Baseline in Iron Parameter Profile of LY3113593</measure>
    <time_frame>Baseline, Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Maximum Absolute Change From Baseline in TSat Parameter Profile of LY3113593</measure>
    <time_frame>Baseline, Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Maximum Change From Baseline in Hemoglobin (Hb) Parameter Profile of LY3113593</measure>
    <time_frame>Baseline, Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>LY3113593 IV (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo matching LY3113593 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3113593 SC (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3113593 administered subcutaneous (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo matching LY3113593 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3113593 IV (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3113593 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo matching LY3113593 administered IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3113593</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3113593 IV (Part A)</arm_group_label>
    <arm_group_label>LY3113593 IV (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3113593</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3113593 SC (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo IV (Part A)</arm_group_label>
    <arm_group_label>Placebo IV (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo SC (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Participants:

               -  Healthy males or females

               -  Participants have a body mass index (BMI) of 18.5 to 29.9 kilogram per meter
                  square (kg/m^2), inclusive at screening

          -  Participants Treated with Hemodialysis:

               -  Participants are males or females who have end-stage renal disease (ESRD) and
                  have been receiving adequate maintenance hemodialysis (3 times weekly) for at
                  least 12 weeks prior to screening

               -  Participants have a hemoglobin value greater than or equal to (≥)9.0 grams per
                  deciliter (g/dL) and less than or equal to (≤)12.5 g/dL at screening

               -  Participants have a body mass index (BMI) of 18.5 to 45.0 kg/m^2, inclusive, at
                  screening

          -  Both Populations:

               -  Male participants agree to use a reliable method of birth control and avoid
                  donating sperm during the study and for 3 months following the dose of the
                  investigational product

               -  Female participants must not be of child-bearing potential

        Exclusion Criteria:

          -  Healthy Participants:

               -  Participants that have a history or presence of cardiovascular, respiratory,
                  hepatic, renal, gastrointestinal, endocrine, hematological, or neurological
                  disorders capable of significantly altering the absorption, metabolism, or
                  elimination of drugs; of constituting a risk when taking the study medication; or
                  of interfering with the interpretation of data

               -  Participants that have used or intend to use over-the-counter or prescription
                  medication, including herbal medications within 14 days prior to dosing

          -  Participants Treated with Hemodialysis:

               -  Participants that have a history of myocardial infarction, acute coronary
                  syndrome, stroke or transient ischemic attacks within the prior 6 months

               -  Participants that have heart failure that results in dyspnea at rest or during
                  minimal exercise

               -  Participants that have poorly controlled hypertension

               -  Participants that have a history of significant thrombotic disease, pulmonary
                  hypertension, significant hematological disease or current liver disease, known
                  hepatic or biliary abnormalities

               -  Participants that had a blood transfusion within the prior 12 weeks or an
                  anticipated need for blood transfusion during the study

               -  Participants that have evidence of active peptic, duodenal, or esophageal ulcer
                  disease or gastrointestinal bleeding within the prior 12 weeks

          -  Both Populations:

               -  Participants that have known allergies to related compounds or any components of
                  the study drug or its formulation, clinically significant multiple or severe drug
                  allergies, or intolerance to topical corticosteroids, or severe post treatment
                  hypersensitivity reactions or history of significant atopy

               -  Participants that have participated, within the last 30 days (or 5 half-lives if
                  long half life) in a clinical trial involving an investigational product

               -  Participants that have known or ongoing psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Early Phase Unit at Glendale</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <results_first_submitted>October 21, 2017</results_first_submitted>
  <results_first_submitted_qc>August 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2019</results_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Part A)</title>
          <description>Single dose of placebo matching LY3113593.</description>
        </group>
        <group group_id="P2">
          <title>LY IV 1.5mg (Part A)</title>
          <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
        </group>
        <group group_id="P3">
          <title>LY IV 5mg (Part A)</title>
          <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
        </group>
        <group group_id="P4">
          <title>LY IV 15mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 15 mg.</description>
        </group>
        <group group_id="P5">
          <title>LY IV 50mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 50 mg.</description>
        </group>
        <group group_id="P6">
          <title>LY IV 150mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 150 mg.</description>
        </group>
        <group group_id="P7">
          <title>LY IV 400mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 400 mg.</description>
        </group>
        <group group_id="P8">
          <title>LY SC 150mg (Part A)</title>
          <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
        </group>
        <group group_id="P9">
          <title>Placebo IV (Part B)</title>
          <description>Single dose of placebo matching LY3113593 administered IV.</description>
        </group>
        <group group_id="P10">
          <title>LY IV 150mg(Part B)</title>
          <description>Single dose of LY3113593 administered IV at 150 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received At Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Part A)</title>
          <description>Single dose of placebo matching LY3113593.</description>
        </group>
        <group group_id="B2">
          <title>LY IV 1.5mg (Part A)</title>
          <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
        </group>
        <group group_id="B3">
          <title>LY IV 5mg (Part A)</title>
          <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
        </group>
        <group group_id="B4">
          <title>LY IV 15mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 15 mg.</description>
        </group>
        <group group_id="B5">
          <title>LY IV 50mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 50 mg.</description>
        </group>
        <group group_id="B6">
          <title>LY IV 150mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 150 mg.</description>
        </group>
        <group group_id="B7">
          <title>LY IV 400mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 400 mg.</description>
        </group>
        <group group_id="B8">
          <title>LY SC 150mg (Part A)</title>
          <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
        </group>
        <group group_id="B9">
          <title>Placebo IV (Part B)</title>
          <description>Single dose of placebo matching LY3113593 administered IV.</description>
        </group>
        <group group_id="B10">
          <title>LY IV 150mg (Part B)</title>
          <description>Single dose of LY3113593 administered IV at 150 mg.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All enrolled participants Age data as per Part in trial.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="10.69"/>
                    <measurement group_id="B2" value="45.0" spread="7.40"/>
                    <measurement group_id="B3" value="31.0" spread="5.22"/>
                    <measurement group_id="B4" value="30.7" spread="4.41"/>
                    <measurement group_id="B5" value="41.5" spread="21.00"/>
                    <measurement group_id="B6" value="46.3" spread="8.89"/>
                    <measurement group_id="B7" value="38.3" spread="7.55"/>
                    <measurement group_id="B8" value="43.7" spread="13.05"/>
                    <measurement group_id="B11" value="39.1" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="2"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B9" value="38.5" spread="13.44"/>
                    <measurement group_id="B10" value="51.7" spread="5.85"/>
                    <measurement group_id="B11" value="48.4" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="2"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="2"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="2"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="2"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
        <description>The number of participants with 1 or more SAEs assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
        <time_frame>Baseline through end of study (Day 85)</time_frame>
        <population>All enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single dose of placebo matching LY3113593.</description>
          </group>
          <group group_id="O2">
            <title>LY IV 1.5mg (Part A)</title>
            <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
          </group>
          <group group_id="O3">
            <title>LY IV 5mg (Part A)</title>
            <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>LY IV 15mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 15 mg.</description>
          </group>
          <group group_id="O5">
            <title>LY IV 50mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 50 mg.</description>
          </group>
          <group group_id="O6">
            <title>LY IV 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
          <group group_id="O7">
            <title>LY IV 400mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 400 mg.</description>
          </group>
          <group group_id="O8">
            <title>LY SC 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
          </group>
          <group group_id="O9">
            <title>Placebo IV (Part B)</title>
            <description>Single dose of LY3113593 administered IV.</description>
          </group>
          <group group_id="O10">
            <title>LY IV 150mg (Part B)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
          <description>The number of participants with 1 or more SAEs assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
          <population>All enrolled participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3113593</title>
        <time_frame>Day 1: pre-dose, 30 minutes, 2 hours, 4 hours, 12 hours; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and 85</time_frame>
        <population>All enrolled participants who received at least one dose of LY3113593 study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY IV 1.5mg (Part A)</title>
            <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
          </group>
          <group group_id="O2">
            <title>LY IV 5mg (Part A)</title>
            <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>LY IV 15mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 15 mg.</description>
          </group>
          <group group_id="O4">
            <title>LY IV 50mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 50 mg.</description>
          </group>
          <group group_id="O5">
            <title>LY IV 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
          <group group_id="O6">
            <title>LY IV 400mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 400 mg.</description>
          </group>
          <group group_id="O7">
            <title>LY SC 150 mg (Part A)</title>
            <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
          </group>
          <group group_id="O8">
            <title>LY IV 150 mg (Part B)</title>
            <description>Single dose of LY3113593 administered IV at 150mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3113593</title>
          <population>All enrolled participants who received at least one dose of LY3113593 study drug.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="559" spread="15"/>
                    <measurement group_id="O2" value="2070" spread="14"/>
                    <measurement group_id="O3" value="6330" spread="13"/>
                    <measurement group_id="O4" value="20000" spread="19"/>
                    <measurement group_id="O5" value="60800" spread="34"/>
                    <measurement group_id="O6" value="170000" spread="13"/>
                    <measurement group_id="O7" value="11300" spread="43"/>
                    <measurement group_id="O8" value="38000" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Curve to Infinity (AUC (0-∞)) of LY3113593</title>
        <time_frame>Day 1: pre-dose, 30 minutes, 2 hours, 4 hours, 12 hours; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and 85</time_frame>
        <population>All enrolled participants who received at least one dose of LY3113593 study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY IV 1.5mg (Part A)</title>
            <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
          </group>
          <group group_id="O2">
            <title>LY IV 5mg (Part A)</title>
            <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
          </group>
          <group group_id="O3">
            <title>LY IV 15mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 15 mg.</description>
          </group>
          <group group_id="O4">
            <title>LY IV 50mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 50 mg.</description>
          </group>
          <group group_id="O5">
            <title>LY IV 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
          <group group_id="O6">
            <title>LY IV 400mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 400 mg.</description>
          </group>
          <group group_id="O7">
            <title>LY SC 150 mg (Part A)</title>
            <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
          </group>
          <group group_id="O8">
            <title>LY IV 150mg (Part B)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Curve to Infinity (AUC (0-∞)) of LY3113593</title>
          <population>All enrolled participants who received at least one dose of LY3113593 study drug.</population>
          <units>nanograms*hour per milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55700" spread="29"/>
                    <measurement group_id="O2" value="280000" spread="14"/>
                    <measurement group_id="O3" value="1100000" spread="9"/>
                    <measurement group_id="O4" value="5240000" spread="17"/>
                    <measurement group_id="O5" value="17000000" spread="28"/>
                    <measurement group_id="O6" value="38300000" spread="17"/>
                    <measurement group_id="O7" value="7640000" spread="37"/>
                    <measurement group_id="O8" value="8270000" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Absolute Bioavailability of LY3113593 SC Versus IV Based on AUC Ratios</title>
        <time_frame>Day 1: pre-dose, 30 minutes, 2 hours, 4 hours, 12 hours; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and 85</time_frame>
        <population>All enrolled participants who received at least one dose of 150mg LY3113593 study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY SC 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
          </group>
          <group group_id="O2">
            <title>LY IV 150mg (Part A)</title>
            <description>Single dose of LY3113593 (LY) administered IV at 150 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Absolute Bioavailability of LY3113593 SC Versus IV Based on AUC Ratios</title>
          <population>All enrolled participants who received at least one dose of 150mg LY3113593 study drug.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7640000" spread="37"/>
                    <measurement group_id="O2" value="17000000" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Absolute Bioavailability</param_type>
            <param_value>0.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Maximum Change From Baseline in Iron Parameter Profile of LY3113593</title>
        <time_frame>Baseline, Day 85</time_frame>
        <population>All enrolled participants who received at least one dose of study drug and had baseline and post baseline iron profile data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single dose of placebo matching LY3113593.</description>
          </group>
          <group group_id="O2">
            <title>LY IV 1.5mg (Part A)</title>
            <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
          </group>
          <group group_id="O3">
            <title>LY IV 5mg (Part A)</title>
            <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>LY IV 15mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 15 mg.</description>
          </group>
          <group group_id="O5">
            <title>LY IV 50mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 50 mg.</description>
          </group>
          <group group_id="O6">
            <title>LY IV 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
          <group group_id="O7">
            <title>LY IV 400mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 400 mg.</description>
          </group>
          <group group_id="O8">
            <title>LY SC 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
          </group>
          <group group_id="O9">
            <title>Placebo IV (Part B)</title>
            <description>Single dose of placebo matching LY3113593 administered IV.</description>
          </group>
          <group group_id="O10">
            <title>LY IV (Part B)</title>
            <description>Single dose of LY3113593 administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Maximum Change From Baseline in Iron Parameter Profile of LY3113593</title>
          <population>All enrolled participants who received at least one dose of study drug and had baseline and post baseline iron profile data.</population>
          <units>micromoles per liter (μmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="12.5"/>
                    <measurement group_id="O2" value="4.12" spread="5.49"/>
                    <measurement group_id="O3" value="9.46" spread="11.6"/>
                    <measurement group_id="O4" value="8.38" spread="5.22"/>
                    <measurement group_id="O5" value="10.23" spread="10.8"/>
                    <measurement group_id="O6" value="13.5" spread="5.68"/>
                    <measurement group_id="O7" value="7.9" spread="9.67"/>
                    <measurement group_id="O8" value="6.97" spread="14.4"/>
                    <measurement group_id="O9" value="3.3" spread="1.98"/>
                    <measurement group_id="O10" value="7.92" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Maximum Absolute Change From Baseline in TSat Parameter Profile of LY3113593</title>
        <time_frame>Baseline, Day 85</time_frame>
        <population>All enrolled participants who received at least one dose of study drug and had baseline and post baseline Tsat profile data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single dose of placebo matching LY3113593.</description>
          </group>
          <group group_id="O2">
            <title>LY IV 1.5mg (Part A)</title>
            <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
          </group>
          <group group_id="O3">
            <title>LY IV 5mg (Part A)</title>
            <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>LY IV 15mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 15 mg.</description>
          </group>
          <group group_id="O5">
            <title>LY IV 50mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 50 mg.</description>
          </group>
          <group group_id="O6">
            <title>LY IV 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
          <group group_id="O7">
            <title>LY IV 400mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 400 mg.</description>
          </group>
          <group group_id="O8">
            <title>LY SC 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
          </group>
          <group group_id="O9">
            <title>Placebo IV (Part B)</title>
            <description>Single dose of placebo matching LY3113593 administered IV.</description>
          </group>
          <group group_id="O10">
            <title>LY IV (Part B)</title>
            <description>Single dose of LY3113593 administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Maximum Absolute Change From Baseline in TSat Parameter Profile of LY3113593</title>
          <population>All enrolled participants who received at least one dose of study drug and had baseline and post baseline Tsat profile data.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="22.00"/>
                    <measurement group_id="O2" value="6.80" spread="10.00"/>
                    <measurement group_id="O3" value="14.80" spread="18.00"/>
                    <measurement group_id="O4" value="15.70" spread="11.00"/>
                    <measurement group_id="O5" value="12.80" spread="23.00"/>
                    <measurement group_id="O6" value="21.00" spread="8.60"/>
                    <measurement group_id="O7" value="07.80" spread="6.65"/>
                    <measurement group_id="O8" value="17.00" spread="16.00"/>
                    <measurement group_id="O9" value="-0.50" spread="14.90"/>
                    <measurement group_id="O10" value="18.30" spread="18.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Maximum Change From Baseline in Hemoglobin (Hb) Parameter Profile of LY3113593</title>
        <time_frame>Baseline, Day 85</time_frame>
        <population>All enrolled participants who received at least one dose of study drug and had baseline and post baseline Hb profile data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single dose of placebo matching LY3113593.</description>
          </group>
          <group group_id="O2">
            <title>LY IV 1.5mg (Part A)</title>
            <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
          </group>
          <group group_id="O3">
            <title>LY IV 5mg (Part A)</title>
            <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
          </group>
          <group group_id="O4">
            <title>LY IV 15mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 15 mg.</description>
          </group>
          <group group_id="O5">
            <title>LY IV 50mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 50 mg</description>
          </group>
          <group group_id="O6">
            <title>LY IV 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 150 mg.</description>
          </group>
          <group group_id="O7">
            <title>LY IV 400mg (Part A)</title>
            <description>Single dose of LY3113593 administered IV at 400 mg.</description>
          </group>
          <group group_id="O8">
            <title>LY SC 150mg (Part A)</title>
            <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
          </group>
          <group group_id="O9">
            <title>Placebo IV (Part B)</title>
            <description>Single dose of placebo matching LY3113593 administered IV.</description>
          </group>
          <group group_id="O10">
            <title>LY IV (Part B)</title>
            <description>Single dose of LY3113593 administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Maximum Change From Baseline in Hemoglobin (Hb) Parameter Profile of LY3113593</title>
          <population>All enrolled participants who received at least one dose of study drug and had baseline and post baseline Hb profile data.</population>
          <units>millimoles per liter of iron (mml/L-Fe)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.269" spread="0.455"/>
                    <measurement group_id="O2" value="0.425" spread="0.363"/>
                    <measurement group_id="O3" value="0.123" spread="0.486"/>
                    <measurement group_id="O4" value="0.205" spread="0.468"/>
                    <measurement group_id="O5" value="0.780" spread="0.38"/>
                    <measurement group_id="O6" value="0.508" spread="0.65"/>
                    <measurement group_id="O7" value="0.165" spread="0.796"/>
                    <measurement group_id="O8" value="0.217" spread="0.306"/>
                    <measurement group_id="O9" value="0.375" spread="0.361"/>
                    <measurement group_id="O10" value="0.568" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All enrolled participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Part A)</title>
          <description>Single dose of placebo matching LY3113593.</description>
        </group>
        <group group_id="E2">
          <title>LY IV 1.5mg (Part A)</title>
          <description>Single dose of LY3113593 (LY) administered IV at a 1.5 milligrams (mg).</description>
        </group>
        <group group_id="E3">
          <title>LY IV 5mg (Part A)</title>
          <description>Single dose of LY3113593 administered intravenous (IV) at 5 mg.</description>
        </group>
        <group group_id="E4">
          <title>LY IV 15mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 15 mg.</description>
        </group>
        <group group_id="E5">
          <title>LY IV 50mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 50 mg.</description>
        </group>
        <group group_id="E6">
          <title>LY IV 150mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 150 mg.</description>
        </group>
        <group group_id="E7">
          <title>LY IV 400mg (Part A)</title>
          <description>Single dose of LY3113593 administered IV at 400 mg.</description>
        </group>
        <group group_id="E8">
          <title>LY SC 150mg (Part A)</title>
          <description>Single dose of LY3113593 administered subcutaneously (SC) at 150 mg.</description>
        </group>
        <group group_id="E9">
          <title>Placebo IV (Part B)</title>
          <description>Single dose of placebo matching LY3113593 administered IV.</description>
        </group>
        <group group_id="E10">
          <title>LY IV (Part B)</title>
          <description>Single dose of LY3113593 administered IV.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

